- Trial phase
- Approved / marketed (IV since 2020, SC since 2026); additional Phase 2/3 studies completed or ongoing.
- Time to market
- Already approved and marketed: IV formulation since March 2020; subcutaneous 'Sarclisa Escena' formulation approved July 9, 2026.
- Why 3/10
- No hard dated catalyst in the next ~12 months: Sarclisa is already approved (2020) and its most recent binary, FDA approval of the subcutaneous 'Sarclisa Escena' formulation on July 9, 2026, has already passed, and at a ~$109B market-cap company (per the H1 2026 6-K report) this one oncology asset is a small concentration, so the near-term share-price driver is limited (score 3, per the approved-drug rule).
Watch Sanofi's quarterly earnings disclosures for Sarclisa/Sarclisa Escena sales growth and launch uptake of the new subcutaneous on-body-injector form, plus any data presentations from completed isatuximab trials (a Phase 3 IV-vs-SC study finished primary completion Jan 30, 2026).
Price Chart
Executive Summary
Sarclisa (isatuximab) is Sanofi's anti-CD38 antibody for multiple myeloma, approved since March 2020 and now covered by several FDA approvals, a supplemental IV-label approval (Oct 2024) and, most recently, the subcutaneous 'Sarclisa Escena' formulation approved July 9, 2026 for all existing indications, described by a locally analyzed Sanofi 6-K as the first anti-cancer treatment delivered via an on-body injector. The drug is a genuine commercial asset but sits inside a ~$109B diversified mega-cap with no pending regulatory binary for it in the next year, so its standalone share-price power is modest.
How It Works
Sarclisa is an antibody drug (an anti-CD38 monoclonal antibody) given by IV infusion or subcutaneous injection. CD38 is a protein found in high amounts on multiple myeloma cancer cells; the drug binds to it, directly killing the cancer cells and flagging them for the body's immune system to destroy.
Trial Status
Local FDA data show three milestones: initial FDA approval (catalyst dated 2020-03-02), a supplemental efficacy approval for the IV form on 2024-10-25, and an Original Approval (Type 3, new dosage form, subcutaneous vial) of 'Sarclisa Escena' on 2026-07-09. A locally analyzed 6-K report (Jul 2026) says the SC approval covers all existing multiple myeloma indications and was supported by the Phase 3 IRAKLIA study showing non-inferior efficacy with shorter administration time and fewer infusion reactions. Local ClinicalTrials.gov data also show a completed investigator-sponsored Phase 3 (NCT05804032, n=514, primary completion Jan 30 2026) comparing IV vs SC isatuximab in newly diagnosed MM, and a completed Phase 2 (NCT04763616, n=37) of isatuximab + cemiplimab in NK/T-cell lymphoma.
The Two-Sided Case
Upcoming Catalysts
- Quarterly Sanofi earnings disclosures detailing Sarclisa/Sarclisa Escena sales and the subcutaneous launch ramp.
- Potential presentation/publication of results from the completed Phase 3 IV-vs-SC isatuximab study (NCT05804032, primary completion Jan 30, 2026) and the completed Phase 2 NK/T-cell lymphoma study.
- Launch/adoption metrics for the Escena on-body injector, and any label-expansion or new-trial announcements for isatuximab.
- Note: no SNY FDA catalyst is scheduled in the next 180 days in local data; company-level watch item is the venglustat FDA decision (target date Nov 25, 2026, per the H1 2026 6-K report), a different drug.
Source Filing
The SecBot filing or press-release report that triggered this drug report:
Sanofi 6-K SNY ·Originating report